Despite not being identified in all patients with PCa, no amplification was verified in BPH samples, showing the high specificity of PCA3. Our results are aligned with previous studies (14,25) and demonstrated the effectiveness of PCA3 as a useful biomarker for PCa discrimination. This evidence concerns the gene PCA3 and benign prostatic hyperplasia.